Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten J Postma

Showing results (101-110 of 485) with videos related to

Pageof 49
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxbanNatasa Ivanovic, Maarten Beinema, Jacobus Rbj Brouwers, et al.
Vaccine|September 24, 2013
Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisationNikolaos Kotsopoulos, Mark P Connolly, Maarten J Postma, et al.
Journal of Crohn'S & Colitis|October 8, 2013
Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosingMark P Connolly, Johan P Kuyvenhoven, Maarten J Postma, et al.
Clinical Therapeutics|February 1, 2017
Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the NetherlandsLisa A de Jong, Evgeni Dvortsin, Kristel J Janssen, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 2, 2022
[Rotavirus vaccination for all Dutch infants]Jan C Wilschut, Patricia C J L Bruijning-Verhagen, Maarten J Postma
Risk Management and Healthcare Policy|June 29, 2026
Health Equity Barriers to Accessing Vaccination and Screening Services in Low- and Middle-Income Countries: A Narrative ReviewRano K Sinuraya, Maarten J Postma, Irma M Puspitasari, et al.
Clinical Therapeutics|October 27, 2010
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluationsStefan Vegter, Mark H Rozenbaum, Roelien Postema, et al.
Pharmacy World & Science : PWS|December 24, 2003
Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospitalSyed Tabish Razi Zaidi, Yahaya Hassan, Maarten J Postma, et al.
International Journal of Environmental Research and Public Health|April 26, 2025
Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in ZimbabweBlessing Dzingirai, Leolin Katsidzira, Maarten J Postma, et al.
Cancer Treatment and Research Communications|September 18, 2025
Trends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severitySudewi Mukaromah Khoirunnisa, Didik Setiawan, Maarten J Postma, et al.
Pageof 49

Showing results (101-110 of 485) with videos related to

Sort By:
Pageof 49
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxbanNatasa Ivanovic, Maarten Beinema, Jacobus Rbj Brouwers, et al.
Vaccine|September 24, 2013
Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisationNikolaos Kotsopoulos, Mark P Connolly, Maarten J Postma, et al.
Journal of Crohn'S & Colitis|October 8, 2013
Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosingMark P Connolly, Johan P Kuyvenhoven, Maarten J Postma, et al.
Clinical Therapeutics|February 1, 2017
Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the NetherlandsLisa A de Jong, Evgeni Dvortsin, Kristel J Janssen, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 2, 2022
[Rotavirus vaccination for all Dutch infants]Jan C Wilschut, Patricia C J L Bruijning-Verhagen, Maarten J Postma
Risk Management and Healthcare Policy|June 29, 2026
Health Equity Barriers to Accessing Vaccination and Screening Services in Low- and Middle-Income Countries: A Narrative ReviewRano K Sinuraya, Maarten J Postma, Irma M Puspitasari, et al.
Clinical Therapeutics|October 27, 2010
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluationsStefan Vegter, Mark H Rozenbaum, Roelien Postema, et al.
Pharmacy World & Science : PWS|December 24, 2003
Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospitalSyed Tabish Razi Zaidi, Yahaya Hassan, Maarten J Postma, et al.
International Journal of Environmental Research and Public Health|April 26, 2025
Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in ZimbabweBlessing Dzingirai, Leolin Katsidzira, Maarten J Postma, et al.
Cancer Treatment and Research Communications|September 18, 2025
Trends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severitySudewi Mukaromah Khoirunnisa, Didik Setiawan, Maarten J Postma, et al.
Pageof 49